Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntelligent Ultrasound Regulatory News (IUG)

  • This share is currently suspended. It was suspended at a price of 12.875
  • There is currently no data for IUG

Replacement - Form 8 (OPD) - IUG

20 Jan 2025 09:06

RNS Number : 9450T
Intelligent Ultrasound Group PLC
20 January 2025
 

Amendment:

 

This form replaces the original announcement at 15:45 on 20th December 2024. Section 3(a) has been amended, with the number of ordinary shares held by Nicholas Avis and connected persons updated from 407,754 to 548,931.

 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Intelligent Ultrasound Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Intelligent Ultrasound Group plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

20 December 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary 1p

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

 

Nil

(2) Cash-settled derivatives:

 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

 

TOTAL:

Nil

Nil

Nil

Nil

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a) Interests in Intelligent Ultrasound Group plc's ordinary shares of 1p each held by the directors of Intelligent Ultrasound Group plc:

 

Director

Number of Ordinary Shares

% of issued share capital

Stuart Gall

1,491,042

0.46%

Helen Jones

149,292

0.05%

Ingeborg Oie

216,216

0.07%

Riccardo Pigliucci

117,648

0.04%

Nicholas Avis

548,931*

0.16%

 

\* The figure included in relation to the number of Nicholas Avis' Intelligent Ultrasound Shares includes 141,177 Intelligent Ultrasound Shares held by his connected persons representing 0.04 per cent. of the Intelligent Ultrasound Shares in issue.

 

b) Rights to subscribe for Interests in Intelligent Ultrasound Group plc's ordinary shares of 1p each held by the directors of Intelligent Ultrasound Group plc:

 

Director

Type

Number of shares under Option

Date of Grant

Fully Vesting Date

Expiry Date

Exercise price per share

Stuart Gall

EMI

545,591

29.05.2018

29.05.2021

29.05.2028

11.25p

Stuart Gall

Non-tax advantaged

1,891,409

29.05.2018

29.05.2021

29.05.2028

11.25p

Helen Jones

EMI

1,000,000

24.04.2020

24.04.2023

24.04.2030

12.00p

Helen Jones

EMI

662,266

21.12.2020

21.12.2023

21.12.2030

15.25p

Stuart Gall

Non-tax advantaged

1,087,498

21.12.2020

21.12.2023

21.12.2030

15.25p

Stuart Gall

EMI

530,428

21.12.2023

21.12.2026

21.12.2033

9.60p

Stuart Gall

Non-tax advantaged

501,322

21.12.2023

21.12.2026

21.12.2033

9.60p

Helen Jones

EMI

302,131

21.12.2023

21.12.2026

21.12.2033

9.60p

Helen Jones

Non-tax advantaged

334,409

21.12.2023

21.12.2026

21.12.2033

9.60p

Note: All option grants listed above vest in tranches over a 36 month period.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

20 January 2025

Contact name:

Helen Jones, Chief Financial Officer

Telephone number:

+44 (0) 29 7220 0500

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEPKKBKCBKKNDB
Date   Source Headline
16th Aug 20247:00 amRNSExercise of Options and Total Voting Rights
14th Aug 20247:00 amRNSHalf-year Report
6th Aug 202411:22 amRNSResult of General Meeting
31st Jul 20247:00 amRNSNotice of Results
18th Jul 20248:19 amRNSProposed sale of Clinical AI Business for £40.5m
18th Jun 20244:54 pmRNSResult of AGM
23rd May 20247:00 amRNSNotice of AGM and 2023 Report and Accounts
7th May 20244:20 pmRNSHolding(s) in Company
1st May 20247:00 amRNSFinal Results
19th Apr 20247:00 amRNSSonolyst launched on Voluson Signature Series
19th Apr 20247:00 amRNSNotice of Results
29th Feb 20247:00 amRNSNHS Scotland Adopts Classroom to Clinic Training
27th Feb 20243:45 pmRNSScanNav FetalCheck Used in Trial Study
9th Feb 20247:00 amRNSLaunch of Portable NeedleTrainer Plus
9th Jan 20247:00 amRNSTrading Update
22nd Dec 20237:00 amRNSGrant of Share Options
27th Nov 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
23rd Nov 20237:00 amRNSLaunch of ScanNav FetalCheck and its use in study
17th Nov 20237:00 amRNSSonoLystlive now standard on Voluson Expert Series
7th Nov 20237:00 amRNSIntelligent Ultrasound signs research agreement
11th Sep 20237:00 amRNSSonoLystlive launched on Voluson Expert Series
17th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
24th Jul 20237:00 amRNSTrading Update
21st Jun 20234:08 pmRNSResult of AGM
26th May 20237:00 amRNSDirectorate Change
26th May 20237:00 amRNSNotice of AGM and 2022 Report and Accounts
22nd May 20233:57 pmRNSHolding(s) in Company
18th May 20237:00 amRNSMello investor conference
20th Apr 20233:15 pmRNSHolding(s) in Company
20th Apr 20237:00 amRNSFinal Results
23rd Mar 20234:45 pmRNSPDMR/PCA Dealing
15th Mar 20237:00 amRNSNotice of Results
16th Jan 20237:00 amRNSTrading update
8th Dec 20227:00 amRNSSupport programme in improving global healthcare
30th Nov 20221:12 pmRNSResult of GM
11th Nov 20227:00 amRNSPlacing and Subscription to raise £5.2 million
20th Oct 20227:00 amRNSScanNav Anatomy PNB clearance for sale in the USA
19th Oct 20222:05 pmRNSSecond Price Monitoring Extn
19th Oct 20222:00 pmRNSPrice Monitoring Extension
23rd Sep 20227:00 amRNSChange of Auditor
2nd Sep 202211:09 amRNSLaunch of NeedleTrainer 2
18th Aug 20227:00 amRNSHalf-year Report
15th Aug 20227:00 amRNSDirectorate Change
8th Aug 20227:00 amRNSNotice of Results
21st Jul 20227:00 amRNSTrading update
20th Jul 20227:00 amRNSAI technology incorporated into Voluson Expert 22
22nd Jun 202212:08 pmRNSResult of AGM
22nd Jun 20227:00 amRNSAGM Statement
21st Jun 202211:05 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.